Compare TBPH & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBPH | KBDC |
|---|---|---|
| Founded | 2013 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 941.8M |
| IPO Year | 2013 | 2018 |
| Metric | TBPH | KBDC |
|---|---|---|
| Price | $13.86 | $13.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $18.50 | $15.40 |
| AVG Volume (30 Days) | ★ 782.6K | 406.3K |
| Earning Date | 05-07-2026 | 03-02-2026 |
| Dividend Yield | N/A | ★ 13.59% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.88 | ★ 1.67 |
| Revenue | ★ $15,386,000.00 | N/A |
| Revenue This Year | $70.90 | $193.84 |
| Revenue Next Year | N/A | $9.00 |
| P/E Ratio | $15.75 | ★ $8.38 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.90 | $13.06 |
| 52 Week High | $21.03 | $16.89 |
| Indicator | TBPH | KBDC |
|---|---|---|
| Relative Strength Index (RSI) | 27.74 | 52.70 |
| Support Level | $13.41 | $13.54 |
| Resistance Level | $14.76 | $14.33 |
| Average True Range (ATR) | 0.58 | 0.36 |
| MACD | -0.08 | 0.04 |
| Stochastic Oscillator | 11.29 | 82.03 |
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.